Friday, September 25, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchcerebrolysinstroketraumatic brain injuryneurorehabilitation

Cerebrolysin evidence stronger in stroke than TBI, neuro-rehab review says

The porcine brain-derived peptide is used in roughly 50 countries but remains unlicensed in the US and UK, complicating patient conversations.

PR
By Priya Raman · Science Reporter
Sep 24 12:09 ETSource: London Post

The wire

  1. 01A neuro-rehabilitation piece summarises Cerebrolysin's evidence base: randomised trials combining it with standard rehab reported motor recovery gains in stroke, while dedicated traumatic brain injury data remain thinner.
  2. 02Clinicians increasingly field questions from patients who encounter peptide therapies via international treatment centres and private clinics, with expectations shaped by marketing rather than trial data.
  3. 03The article is a commentary, not new data, and names a research supplier; it notes reviews stop short of firm TBI conclusions and that sourcing and manufacturing standards vary widely.

From the source

Neuroplasticity After Brain Injury: Why Peptide Signalling Is Becoming a Research Focus

Neuroplasticity, the brain’s capacity to rewire and reorganise itself after injury, sits at the heart of everything neuro-rehab does.

Read at london-post.co.uk
PeptiPrescribed peptides from $99/moSee all →